News

Optibrium Adds Augmented Intelligence for Compound Design to its StarDrop Small Molecule Drug Discovery Software

Mar 1, 2022

Optibrium Adds Augmented Intelligence for Compound Design to its StarDrop Small Molecule Drug Discovery Software

 

New Inspyra™ module combines chemists’ expertise with exploratory capabilities of automated compound design.

Inspyra™ provides drug designers direct access to powerful AI capabilities, supporting established workflows.

CAMBRIDGE, UK, 01 March 2022 – Optibrium™, a leading developer of software for drug discovery, today announced the release of the latest version of StarDrop™, its comprehensive software platform for small molecule design, optimisation and data analysis. More than 160 organisations currently use StarDrop, including many of the world’s leading pharmaceutical companies. The new release introduces Inspyra™, a module that dynamically learns from chemists’ expert knowledge and feedback to guide automated compound design methods, creating a powerful ‘augmented intelligence’ to accelerate the discovery of high-quality drug candidates.

The impact of ‘generative chemistry’ algorithms for automated compound design is often limited in practice by a lack of alignment with chemists’ existing workflows and know-how, resulting in irrelevant compound suggestions. StarDrop’s new Inspyra™ module addresses this limitation by combining exploratory capabilities of automated compound design with chemists’ expertise, helping to focus on the most relevant chemistry spaces and suggest optimisation strategies with the highest potential for a project.

Inspyra™ has been developed in collaboration with global pharmaceutical companies, and has already been applied successfully across several hit-to-lead and lead optimisation projects. The module leverages StarDrop’s predictive modelling and data visualisation capabilities, multi-parameter optimisation, and 2D and 3D structure-activity-relationship (SAR) analysis, delivering a comprehensive solution for small molecule optimisation that reduces cost and time while increasing the chance of successful drug discovery.

Dr Peter Hunt, Director of Computational Chemistry at Optibrium, said: “Having led groups at Novartis and MSD, access to an intuitive tool like the new Inspyra module for StarDrop would have been invaluable. While I am a firm believer in the benefits of automated compound idea generation, time and time again, colleagues were frustrated looking at compound suggestions that were not relevant to them for one reason or another. Inspyra is the first approach to address this challenge, and we are proud to release this new StarDrop version with unprecedented automated compound design support.”

Read the Press Release >